Recordati Rare Patent-Cliff Exposure & CMS Drug Spending Portfolio

Recordati Rare (US): 3 reconciled FDA prescription therapies, $19.5M 2024 CMS Part D & Medicaid spend, and 51 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies3
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$19.5M
2024 Medicare Part D Spend$9.5M
2024 Medicaid Spend$10.0M
California HCAI SB 17 Filings51 WAC filings (max 37.8% 2-yr change)